FORT DETRICK, Md. –
On August 13, 2024, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) participated in a kick-off meeting with Phlow Corporation at its facility in Petersburg, Virginia. This meeting marked the start of work on a JPEO-CBRND-led advanced manufacturing effort for active pharmaceutical ingredients, which are used to develop medical countermeasure drug products that support the joint force and its allies in counteracting chemical and biological (CB) threats.
This effort is conducted under an interagency agreement with the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR), which is a larger, 10-year, $1.2 billion, Cost Plus Fixed Fee contract awarded to Phlow Corp. on May 18, 2020. The contract supports the broader Department of Defense objective of expanding the domestic industrial base to reduce the inventory risk of a single source, while also mitigating capability fielding and operational readiness risks.
“This interagency partnership between the JPEO-CBRND and HHS-ASPR is critical to the National Defense Strategy and exemplifies the ongoing commitment to enhance rapid response capabilities and increase operational readiness with a domestic source of supply—compatible with HHS requirements—to ensure effective emergency response across agencies,” said COL Matthew Clark, Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the JPEO-CBRND. “The JPEO-CBRND mission is complementary to the HHS health mission, and this partnership highlights our shared commitment in continuing to provide a layered defense against CB threats to the warfighter.”
On August 13, 2024, the JPM CBRN Medical team kicked off an interagency effort with Phlow Corporation.
Pictured Left to Right: Matt Fitzgerald, Brendon Doyle, Andriy Neshchadin, LTC Edwin Kolen, Andy Carpenter, LCDR Fred Kelly, Kevin Watts, Chris Dosier, Skip Joyce, Matt Magyar and Joan Beck.
###
About the JPEO-CBRND: The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the joint force across combined Joint All-Domain Operations. The JPEO-CBRND’s goal is to enable the joint force to fight and win unencumbered by a CBRN environment. To learn more about the JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.
About the JPM CBRN Medical: The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability.
Disclaimer: The views and opinions expressed herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply endorsement, recommendation, or favoring by the United States government and shall not be used for advertising or product endorsement purposes.